Prognostic role of metformin in diabetes mellitus type 2 patients with hepatocellular carcinoma: A systematic review and meta-analysis

doi:10.4239/wjd.v14.i8.1289

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 14, Issue 8

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (2278)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-4) series, Tables (1-3) series.

Item

Count

PDF

WORD

HTML

1030

Figures (1-4)

238

Tables (1-3)

240

Sum=1583

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

130

Download

429

Sum=559

Aug 15, 2023 (publication date) through Jun 13, 2024

Times Cited of This Article

Times Cited (0)

Journal Information of This Article

Publication Name

World Journal of Diabetes

ISSN

1948-9358

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Meta-Analysis

World J Diabetes. Aug 15, 2023; 14(8): 1289-1300
Published online Aug 15, 2023. doi: 10.4239/wjd.v14.i8.1289

Full Size Figure Download Figure

Figure 3 Forest plots and meta-analyses results. A: The occurrence of death after any hepatocellular carcinoma (HCC) treatment and only after curative therapies: Metformin vs no metformin in type 2 diabetes mellitus (T2DM) patients; B: The occurrence of progressive tumor disease and HCC recurrence after any HCC treatment: Metformin vs no metformin in T2DM patients. HCC: Hepatocellular carcinoma.

Citation: Cigrovski Berkovic M, Giovanardi F, Mrzljak A, Lai Q. Prognostic role of metformin in diabetes mellitus type 2 patients with hepatocellular carcinoma: A systematic review and meta-analysis. World J Diabetes 2023; 14(8): 1289-1300
URL: https://www.wjgnet.com/1948-9358/full/v14/i8/1289.htm
DOI: https://dx.doi.org/10.4239/wjd.v14.i8.1289